The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
Open accessAbstract
The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with prostate-specific membrane antigen (PSMA)–positive tumor phenotype. Methods: A dosimetry estimate was calculated on the basis of time–activity curves derived from serially obtained 177Lu-PSMA-617 scans extrapolated to the physical half-life of 225Ac, assuming instant decay of unstable daughter nuclides. Salvage therapies empirically conducted with 50 (n = 4), 100 (n = 4), 150 (n = 2), and 200 kBq/kg (n = 4) of 225Ac-PSMA-617 were evaluated retrospectively regarding toxicity and treatment response. Eight of 14 patients received further cycles in either 2- or 4-mo intervals with identical or deescalated activities. Results: Dosimetry estimates for 1 MBq of 225Ac-PSMA-617 assuming a relative biologic effectiveness of 5 revealed mean doses of 2.3 Sv for salivary glands, 0.7 Sv for kidneys, and 0.05 Sv for red marrow that are composed of 99.4% α, 0.5% β, and 0.1% photon radiation, respectively. In clinical application, severe xerostomia became the dose-limiting toxicity if treatment activity exceeded 100 kBq/kg per cycle. At 100 kBq/kg, the duration of prostate-specific antigen decline was less than 4 mo, but if therapy was repeated every 2 mo patients experienced additive antitumor effects. Treatment activities of 50 kBq/kg were without toxicity but induced insufficient antitumor response in these high-tumor-burden patients. Remarkable antitumor activity by means of objective radiologic response or tumor marker decline was observed in 9 of 11 evaluable patients. Conclusion: For advanced-stage patients, a treatment activity of 100 kBq/kg of 225Ac-PSMA-617 per cycle repeated every 8 wk presents a reasonable trade-off between toxicity and biochemical response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, current clinical TAT research relies greatly on indirect approximation by extrapolating pre-existing 177Lu-labeled pharmaceuticals (84, 112, 113).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [84]
In the citing paper
“However, a low probability of γ-emission and overlapping Bremsstrahlung due to β-emitters in the 225Ac decay chain preclude simultaneous treatment and dosimetry measurement in a clinical setting (84).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
(1997) · PubMed · Cited by 1,541
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,187
Self-citationRahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M. A., Essler, M., Baum, R. P., Kulkarni, H., Schmidt, M. C., Drzezga, A. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 861
Self-citationKratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Self-citationBenešová, M., Schäfer, M. K.-H., Bauder‐Wüst, U., Afshar‐Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147413 · Cited by 621
Self-citationGiesel, F. L., Hadaschik, B. A., Cardinale, J., Radtke, J. P., Vinsensia, M., Lehnert, W., Kesch, C. V., Tolstov, Y. L., Singer, S., Grabe, N., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3573-4 · Cited by 595
Self-citationSgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Tumor therapy with targeted atomic nanogenerators.
McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science · doi:10.1126/science.1064126 · Cited by 501
Cited by
Sorted by citations
Items 101–200 of 504
203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer
Li, M., Sagastume, E. A., Lee, D., McAlister, D. R., DeGraffenreid, A. J., Olewine, K. R., Graves, S. A., Copping, R., Mirzadeh, S., Zimmerman, B. E., et al. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200727190423 · Cited by 58
Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects
Klauser, P. C., Chopra, S., Cao, L., Bobba, K. N., Yu, B., Seo, Y., Chan, E., Flavell, R. R., Evans, M. J., & Wang, L. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00288 · Cited by 58
Internal microdosimetry of alpha-emitting radionuclides
HOFMANN, W., Li, W. B., Friedland, W., Miller, B. W., Madas, B. G., Bardiès, M., & Balásházy, I. (2019) · Radiation and Environmental Biophysics · doi:10.1007/s00411-019-00826-w · Cited by 59
Global experience with PSMA-based alpha therapy in prostate cancer
Sathekge, M. M., Bruchertseifer, F., Vorster, M., Morgenstern, A., & Lawal, I. O. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05434-9 · Cited by 58
Self-citationBernhardt, P., Svensson, J. B., Hemmingsson, J., van der Meulen, N. P., Zeevaart, J. R., Konijnenberg, M., Müller, C., & Kindblom, J. (2021) · Cancers · doi:10.3390/cancers13092011 · Cited by 55
Radiation Dosimetry in 177Lu-PSMA-617 Therapy
Jackson, P. A., Hofman, M. S., McIntosh, L., Buteau, J. P., & Kumar, A. S. R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2021.11.003 · Cited by 58
PSMA ligands in prostate cancer – Probe optimization and theranostic applications
Lütje, S., Slavik, R., Fendler, W. P., Herrmann, K., & Eiber, M. (2017) · Methods · doi:10.1016/j.ymeth.2017.06.026 · Cited by 55
Sathekge, M. M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Mokoala, K. M. G., Reed, J., Maseremule, L., Ndlovu, H., Hlongwa, K. N., Maes, A., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06165-9 · Cited by 54
Self-citationHe, L., Fang, H., Chen, C., Wu, Y., Wang, Y., Ge, H., Wang, L., Wan, Y., & He, H. (2020) · Medicine · doi:10.1097/md.0000000000019760 · Cited by 55
α‐Emitting cancer therapy using 211At‐AAMT targeting LAT1
Kaneda‐Nakashima, K., Zhang, Z., Manabe, Y., Shimoyama, A., Kabayama, K., Watabe, T., Kanai, Y., Ooe, K., Toyoshima, A., Shirakami, Y., et al. (2020) · Cancer Science · doi:10.1111/cas.14761 · Cited by 54
Delker, A., Schleske, M., Liubchenko, G., Berg, I., Zacherl, M. J., Brendel, M., Gildehaus, F. J., Rumiantcev, M., Resch, S., Hürkamp, K., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06092-1 · Cited by 56
Ahmadzadehfar, H., Rahbar, K., Essler, M., & Biersack, H. J. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.07.003 · Cited by 53
Sarnelli, A., Belli, M. L., Iorio, V. D., Mezzenga, E., Celli, M., Severi, S., Tardelli, E., Nicolini, S., Oboldi, D., Uccelli, L., et al. (2019) · Molecules · doi:10.3390/molecules24030621 · Cited by 52
Melanocortin 1 Receptor–Targeted α-Particle Therapy for Metastatic Uveal Melanoma
Tafreshi, N. K., Tichacek, C. J., Pandya, D. N., Doligalski, M. L., Budzevich, M. M., Kil, H., Bhatt, N., Kock, N. D., Messina, J. L., Ruiz, E., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.217240 · Cited by 54
From Bench to Bedside—The Bad Berka Experience With First-in-Human Studies
Zhang, J., Singh, A., Kulkarni, H., Schuchardt, C., Müller, D., Wester, H.-J., Μάινα, Θ., Rösch, F., van der Meulen, N. P., Müller, C., et al. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.06.002 · Cited by 54
Królicki, L., Bruchertseifer, F., Kunikowska, J., Koziara, H. M., Pawlak, D., Kuliński, R., Rola, R., Merlo, A., & Morgenstern, A. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05350-y · Cited by 53
Self-citationPandit-Taskar, N. D., Iravani, A., Lee, D., Jacene, H. A., Pryma, D. A., Hope, T. A., Saboury, B., Capala, J., & Wahl, R. L. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262977 · Cited by 55
Dosimetry in targeted alpha therapy. A systematic review: current findings and what is needed
Tronchin, S., Forster, J. C., Hickson, K., & Bezak, E. (2022) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ac5fe0 · Cited by 55
Langbein, T., Kulkarni, H., Schuchardt, C., Müeller, D., Volk, G. F., & Baum, R. P. (2022) · Diagnostics · doi:10.3390/diagnostics12081926 · Cited by 53
de Roode, K. E., Joosten, L., & Béhé, M. P. (2024) · Pharmaceuticals · doi:10.3390/ph17020256 · Cited by 50
Behr, S. C., Aggarwal, R. R., VanBrocklin, H. F., Flavell, R. R., Gao, K. T., Small, E. J., Blecha, J. E., Jivan, S., Hope, T. A., Simko, J., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.220715 · Cited by 50
Mitran, B., Rinne, S. S., Konijnenberg, M., Μάινα, Θ., Nock, B. A., Altai, M., Vorobyeva, A., Larhed, M., Максимилианович, Т. В., de Jong, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32401 · Cited by 50
Prostate-specific membrane antigen theranostics
Ferdinandus, J., Violet, J. A., Sandhu, S. K., & Hofman, M. S. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000486 · Cited by 51
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
Ruigrok, E. A. M., Tamborino, G., de Blois, E., Roobol, S. J., Verkaik, N. S., Saint‐Hubert, M. D., Konijnenberg, M., van Weerden, W. M., de Jong, M., & Nonnekens, J. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05821-w · Cited by 50
In vitro evaluation of 225Ac‐DOTA‐substance P for targeted alpha therapy of glioblastoma multiforme
Majkowska‐Pilip, A., Rius, M., Bruchertseifer, F., Apostolidis, C., Weis, M., Bonelli, M., Laurenza, M., Królicki, L., & Morgenstern, A. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13199 · Cited by 48
Self-citationLadjohounlou, R., Lozza, C., Pichard, A., Constanzo, J., Karam, J., Fur, P. L., Deshayes, E., Boudousq, V., Paillas, S., Busson, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3295 · Cited by 48
Self-citationTateishi, U. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa004 · Cited by 48
Establishment of a clinical SPECT/CT protocol for imaging of 161Tb
Marin, I., Rydèn, T., van Essen, M., Svensson, J. B., Gracheva, N., Köster, U., Zeevaart, J. R., van der Meulen, N. P., Müller, C., & Bernhardt, P. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-00314-x · Cited by 48
Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments
Farolfi, A., Fendler, W. P., Iravani, A., Haberkorn, U., Hicks, R. J., Herrmann, K., Walz, J. C., & Fanti, S. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.01.001 · Cited by 47
Self-citationAtomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management
Roscher, M., Bakos, G., & Benešová, M. (2020) · Pharmaceuticals · doi:10.3390/ph13040076 · Cited by 47
Targeted nuclear medicine. Seek and destroy
Максимилианович, Т. В., Чернов, В. И., & Deyev, S. M. (2021) · Russian Chemical Reviews · doi:10.1070/rcr5034 · Cited by 47
Benabdallah, N., Scheve, W., Dunn, N., Silvestros, D., Schelker, P., Abou, D. S., Jammalamadaka, U. M., Laforest, R. A., Li, Z., Liu, J., et al. (2021) · Theranostics · doi:10.7150/thno.63860 · Cited by 46
Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT
Gosewisch, A., Schleske, M., Gildehaus, F. J., Berg, I., Kaiser, L., Brosch-Lenz, J., Bartenstein, P., Todica, A. S., Ilhan, H., & Böning, G. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05024-1 · Cited by 46
Privé, B. M., Derks, Y. H. W., Rosar, F., Franssen, G. M., Peters, S. M. B., Khreish, F., Bartholomä, M. D., Maus, S., Gotthardt, M., Laverman, P., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05661-0 · Cited by 46
Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond
Gafita, A., Marcus, C. V., Kostos, L. K., Schuster, D. M., Calais, J., & Hofman, M. S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_350946 · Cited by 47
Rathke, H. G., Afshar‐Oromieh, A., Giesel, F. L., Kremer, C., Flechsig, P., Haufe, S., Mier, W., Holland‐Letz, T., de Bucourt, M., Armor, T., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200220 · Cited by 43
Self-citationPSMA Theranostics: Science and Practice
Mokoala, K. M. G., Lawal, I. O., Lengana, T., Kgatle, M., Giesel, F. L., Vorster, M., & Sathekge, M. M. (2021) · Cancers · doi:10.3390/cancers13153904 · Cited by 44
Self-citationDadgar, H., Pashazadeh, A., Norouzbeigi, N., Assadi, M., Albalooshi, B., Baum, R. P., Al‐Ibraheem, A., Haidar, M., Beheshti, M., Geramifar, P., et al. (2025) · Theranostics · doi:10.7150/thno.107963 · Cited by 43
Shen, C. J., Minn, I., Hobbs, R. F., Chen, Y., Josefsson, A., Brummet, M. E., Banerjee, S. R., Brayton, C. F., Mease, R. C., Pomper, M. G., et al. (2020) · Theranostics · doi:10.7150/thno.38882 · Cited by 42
Liubchenko, G., Böning, G., Zacherl, M. J., Rumiantcev, M., Unterrainer, L. M., Gildehaus, F. J., Brendel, M., Resch, S., Bartenstein, P., Ziegler, S. I., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06681-2 · Cited by 42
68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer
Sachpekidis, C., Bäumer, P., Kopka, K., Hadaschik, B. A., Hohenfellner, M., Kopp‐Schneider, A., Haberkorn, U., & Dimitrakopoulou‐Strauss, A. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3936-0 · Cited by 41
Self-citationZhang, J., Kulkarni, H., & Baum, R. P. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002915 · Cited by 41
Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward
Feijtel, D., de Jong, M., & Nonnekens, J. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200226104652 · Cited by 42
Theoretical Study of Actinide Complexes with Macropa
Kovács, A. (2020) · ACS Omega · doi:10.1021/acsomega.0c02873 · Cited by 43
Sen, I. B., Thakral, P., Tiwari, P., Pant, V., Das, S. S., Manda, D., & Raina, V. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01617-4 · Cited by 41
Rubira, L., Deshayes, E., Santoro, L., Kotzki, P. O., & Fersing, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041051 · Cited by 41
Ballal, S., Yadav, M. P., Satapathy, S., Raju, S., Tripathi, M., Damle, N. A., Sahoo, R. K., & Bal, C. S. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06340-y · Cited by 40
Jalloul, W., Ghizdovăţ, V., Stolniceanu, C. R., Ionescu, T. M., Grierosu, I. C., Păvăleanu, I., Moscalu, M., & Ştefănescu, C. (2023) · Pharmaceuticals · doi:10.3390/ph16121679 · Cited by 40
Chakravarty, R., Siamof, C. M., Dash, A. K., & Cai, W. (2018) · Europe PMC (PubMed Central) · Cited by 40
Harsini, S., Saprunoff, H., Alden, T., Mohammadi, B., Wilson, D. C., & Bénard, F. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.246983 · Cited by 40
Ballal, S., Yadav, M. P., Sahoo, R. K., Tripathi, M., Dwivedi, S. N., & Bal, C. (2021) · The Prostate · doi:10.1002/pros.24137 · Cited by 40
Lee, D. Y., & Kim, Y.-I. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262017 · Cited by 40
Rizzo, A., Dall’Armellina, S., Pizzuto, D. A., Perotti, G., Zagaria, L., Lanni, V., Treglia, G., Racca, M., & Annunziata, S. (2022) · Cancers · doi:10.3390/cancers14164039 · Cited by 40
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?
Feuerecker, B., Kratochwil, C., Ahmadzadehfar, H., Morgenstern, A., Eiber, M., Herrmann, K., & Pomykala, K. L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265353 · Cited by 39
Self-citationRadiometals in Imaging and Therapy: Highlighting Two Decades of Research
Sharma, S., & Pandey, M. K. (2023) · Pharmaceuticals · doi:10.3390/ph16101460 · Cited by 39
Boinapally, S., Ahn, H.-H., Cheng, B., Brummet, M. E., Nam, H., Gabrielson, K. L., Banerjee, S. R., Minn, I., & Pomper, M. G. (2021) · Scientific Reports · doi:10.1038/s41598-021-86551-1 · Cited by 39
Sudo, H., Tsuji, A. B., Sugyo, A., Nagatsu, K., Minegishi, K., Ishioka, N. S., Ito, H., Yoshinaga, K., & Higashi, T. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.04.008 · Cited by 38
Ray, S., Lisok, A., Minn, I., Josefsson, A., Kumar, V., Brummet, M. E., Boinapally, S., Brayton, C. F., Mease, R. C., Sgouros, G., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.256388 · Cited by 38
The Role of Theranostics in Prostate Cancer
O’Dwyer, E., Bodei, L., & Morris, M. J. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.07.004 · Cited by 41
Tafreshi, N. K., Kil, H., Pandya, D. N., Tichacek, C. J., Doligalski, M. L., Budzevich, M. M., Delva, N. C., Langsen, M., Vallas, J. A., Boulware, D. C., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00035 · Cited by 40
Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications
Trujillo-Nolasco, M., Morales-Ávila, E., Cruz-Nova, P., Katti, K. V., & Ocampo‐García, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081123 · Cited by 38
Filippi, L., Urso, L., Bianconi, F., Palumbo, B., Marzola, M. C., Evangelista, L., & Schillaci, O. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2192351 · Cited by 37
Okarvi, S. M. (2019) · Clinical and Translational Imaging · doi:10.1007/s40336-019-00326-3 · Cited by 37
Ukon, N., Zhao, S., Washiyama, K., Oriuchi, N., Tan, C., Shimoyama, S., Aoki, M., Kubo, H., Takahashi, K., & Ito, H. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-00326-7 · Cited by 38
Pharmacological Optimization of PSMA-Based Radioligand Therapy
van der Gaag, S., Bartelink, I. H., Vis, A. N., Burchell, G. L., Oprea‐Lager, D. E., & Hendrikse, H. (2022) · Biomedicines · doi:10.3390/biomedicines10123020 · Cited by 37
Rathke, H. G., Winter, E., Bruchertseifer, F., Röhrich, M., Giesel, F. L., Haberkorn, U., Morgenstern, A., & Kratochwil, C. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.267206 · Cited by 36
Self-citationRadium and other alpha emitters in prostate cancer
Sartor, O. A., & Sharma, D. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2018.02.07 · Cited by 36
Fiaccabrino, D., Kunz, P., & Radchenko, V. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.01.003 · Cited by 36
Muniz, M., Loprinzi, C. L., Orme, J. J., Koch, R. M., Mahmoud, A. M., Kase, A. M., Riaz, I. B., Andrews, J. R., Thorpe, M. P., Johnson, G. B., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102748 · Cited by 35
The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors
Pruis, I. J., van Dongen, G. A. M. S., & Veldhuijzen van Zanten, S. E. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031029 · Cited by 35
225Ac Prostate-Specific Membrane Antigen Posttherapy α Imaging: Comparing 2 and 3 Photopeaks
Usmani, S., Rasheed, R., Al kandari, F., Marafi, F., & Naqvi, S. A. R. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002525 · Cited by 35
Liu, Y., Watabe, T., Kaneda‐Nakashima, K., Ooe, K., Shirakami, Y., Toyoshima, A., Shimosegawa, E., Nakano, T., Shinohara, A., & Hatazawa, J. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100757 · Cited by 35
First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
Nulent, T. J. W. K., van Es, R. J. J., Willems, S. M., Braat, A. J. A. T., Devriese, L. A., de Bree, R., & de Keizer, B. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00866-8 · Cited by 35
Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer
Rodak, M., Dekempeneer, Y., Wojewódzka, M., Caveliers, V., Covens, P., Miller, B. W., Sevenois, M. B., Bruchertseifer, F., Morgenstern, A., Lahoutte, T., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-1021 · Cited by 35
Self-citationTargeted alpha-particle therapy: imaging, dosimetry, and radiation protection
Laßmann, M., & Eberlein, U. (2018) · Annals of the ICRP · doi:10.1177/0146645318756253 · Cited by 36
The potential of PSMA-targeted alpha therapy in the management of prostate cancer
Filippi, L., Chiaravalloti, A., Schillaci, O., & Bagni, O. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1814151 · Cited by 34
Belli, M. L., Sarnelli, A., Mezzenga, E., Cesarini, F., Caroli, P., Iorio, V. D., Strigari, L., Cremonesi, M., Romeo, A., Nicolini, S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.531660 · Cited by 34
Wang, X., Shirke, A. A., Walker, E., Sun, R., Ramamurthy, G., Wang, J., Shan, L., Mangadlao, J. D., Dong, Z., Li, J., et al. (2021) · Cancers · doi:10.3390/cancers13030417 · Cited by 34
Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
Kaewput, C., & Vinjamuri, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102738 · Cited by 36
Watabe, T., Liu, Y., Kaneda‐Nakashima, K., Sato, T., Shirakami, Y., Ooe, K., Toyoshima, A., Shimosegawa, E., Wang, Y., Haba, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169434 · Cited by 34
O’Donoghue, J. A., Danila, D. C., Pandit-Taskar, N. D., Beylergil, V., Cheal, S. M., Fleming, S. E., Fox, J. J., Ruan, S., ZANZONICO, P. B., Ragupathi, G., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00326 · Cited by 34
Dekempeneer, Y., Massa, S., Santens, F., Navarro, L., Berdal, M., Lucero, M. M., Antunes, A. R. P., Lahoutte, T., Ginderachter, J. A. V., Devoogdt, N., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266381 · Cited by 33
Bäck, T. A., Jennbacken, K., Thulin, M. H., Lindegren, S., Jensen, H. J., Olafsen, T., Yazaki, P. J., Palm, S., Albertsson, P., Damber, J., et al. (2020) · EJNMMI Research · doi:10.1186/s13550-020-0600-z · Cited by 33
Targeted α Therapies for the Treatment of Bone Metastases
Zustovich, F., & Barsanti, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010074 · Cited by 32
Lee, D., Li, M., Bednarz, B. P., & Schultz, M. K. (2018) · Radiation Research · doi:10.1667/rr15081.1 · Cited by 33
Kesavan, M., Turner, J. H., Meyrick, D. P., Yeo, S. E. K., CARDACI, G. T., & Lenzo, N. P. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2403 · Cited by 32
Soeda, F., Watabe, T., Naka, S., Liu, Y., Horitsugi, G., Neels, O. C., Kopka, K., Tatsumi, M., Shimosegawa, E., Giesel, F. L., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223479 · Cited by 32
Self-citationProstate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer
Sun, M., Niaz, M. J., Niaz, M. O., & Tagawa, S. T. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01042-w · Cited by 35
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Awang, Z. H., Essler, M., & Ahmadzadehfar, H. (2018) · Radiation Oncology · doi:10.1186/s13014-018-1037-7 · Cited by 31
Computer-Assisted Design of Macrocyclic Chelators for Actinium-225 Radiotherapeutics
Morgenstern, A., Lilley, L. M., Stein, B. W., Kozimor, S. A., Batista, E. R., & Yang, P. X. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c02432 · Cited by 31
Self-citationSingh, B., Sharma, S., Bansal, P., Hooda, M., Singh, H., Parihar, A. S., Kumar, A., Watts, A., Mohan, R. M., & Singh, S. K. (2020) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001361 · Cited by 31
Mittlmeier, L. M., Brendel, M., Beyer, L., Albert, N. L., Todica, A. S., Zacherl, M. J., Wenter, V., Herlemann, A., Kretschmer, A., Ledderose, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.663631 · Cited by 31
Tailoring radiotherapies and nanotechnology for targeted treatment of solid tumors
Khan, M. I., Batool, F., Ali, R., Zahra, Q. U. A., Wang, W., Li, S., Wang, G., Liu, L., Khan, S. U., Mansoor, M., et al. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214757 · Cited by 32
A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
Alam, R., Singh, S. B., Thapaliya, S., Shrestha, S., Deo, S., & Khanal, K. (2022) · Cureus · doi:10.7759/cureus.29369 · Cited by 34
Tandem Isotope Therapy with 225 Ac- and 177 Lu-PSMA-617 in a Murine Model of Prostate Cancer
Meyer, C. A. L., Stuparu, A. D., Lückerath, K., Calais, J., Czernin, J. G., Slavik, R., & Dahlbom, M. L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265433 · Cited by 31
Quantitative SPECT/CT imaging of actinium-225 for targeted alpha therapy of glioblastomas
Tulik, M., Kuliński, R., Tabor, Z., Brzozowska, B., Łaba, P., Bruchertseifer, F., Morgenstern, A., Królicki, L., & Kunikowska, J. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00635-1 · Cited by 32
Self-citationStenberg, V. Y., Juzeniene, A., Bruland, Ø. S., & Larsen, R. H. (2020) · Current Radiopharmaceuticals · doi:10.2174/1874471013666200511000532 · Cited by 30
Systemic Radiotherapy of Bone Metastases With Radionuclides
Murray, I., & Du, Y. (2021) · Clinical Oncology · doi:10.1016/j.clon.2020.11.028 · Cited by 33
PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer
Parsi, M., Desai, M. H., Desai, D., Singhal, S., Khandwala, P., & Potdar, R. R. (2021) · Medical Oncology · doi:10.1007/s12032-021-01537-3 · Cited by 30
Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study
Stuparu, A. D., Meyer, C. A. L., Axelsson, S. E., Lückerath, K., Liu, W., Kim, W., Poddar, S., Mona, C. E., Dahlbom, M., Girgis, M. D., et al. (2020) · Theranostics · doi:10.7150/thno.42228 · Cited by 30
Metadata
- Authors
- Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A.
- Affiliations
- University Hospital Heidelberg (DE)
- European Commission (BE)
- ABX-CRO Advanced Pharmaceutical Services (Germany) (DE)
- Pathologisches Institut (DE)
- German Cancer Research Center (DE)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-04-13
- Volume
- 58
- Issue
- 10
- Pages
- 1624-1631
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2606187374
- Cited by
- 505
- References
- 31
- Citations by year
- 2026: 35 · 2025: 60 · 2024: 48 · 2023: 36 · 2022: 53 · 2021: 83 · 2020: 57 · 2019: 61 · 2018: 57 · 2017: 14
- FWCI
- 39.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Joint Research Centre (European Commission) (submittedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- metastatic castration-resistant prostate cancer, dosimetry, 177Lu-PSMA-617, xerostomia, salvage therapy, PSA response, treatment toxicity
- MeSH terms
- Actinium, Aged, Alpha Particles, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Male, Middle Aged, Neoplasm Metastasis, Radiometry, Radiotherapy Dosage, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
